-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, HPeJMBu0nxjI9BCBRJFQbF/oxTd/CyBkcOgbs41l69Iy3oS8V58A1UHXsDnQIBc+ IDU+nEQs3QGpJtdIJLoAVQ== 0000950133-97-002571.txt : 19970724 0000950133-97-002571.hdr.sgml : 19970724 ACCESSION NUMBER: 0000950133-97-002571 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19970723 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: LA JOLLA PHARMACEUTICAL CO CENTRAL INDEX KEY: 0000920465 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 330361285 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-44849 FILM NUMBER: 97644336 BUSINESS ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 6194526600 MAIL ADDRESS: STREET 1: 6455 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: BB BIOTECH AG CENTRAL INDEX KEY: 0000924223 STANDARD INDUSTRIAL CLASSIFICATION: UNKNOWN SIC - 0000 [0000] STATE OF INCORPORATION: DC FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 BUSINESS PHONE: 2028351882 MAIL ADDRESS: STREET 1: C/O BAKER & MCKENZIE STREET 2: 815 CONNECTICUT AVENUE NW CITY: WASHINGTON STATE: DC ZIP: 20006 SC 13D/A 1 LA JOLLA PHARMACEUTICALS SCHEDULE 13D/AMEND. #1. 1 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO SCHEDULE 13D Under the Securities Exchange Act of 1934 LA JOLLA PHARMACEUTICAL COMPANY ------------------------------- (Name of Issuer) COMMON STOCK ------------ (Title of Class of Securities) 503 459 109 ----------- (CUSIP Number) DR. ANDREAS BREMER GRAFENAUWEG 4, 6301 ZUG CH/SWITZERLAND 011-41-41-724-5959 ------------------ (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) Copy to: Daniel L. Goelzer, Esq. Baker & McKenzie 815 Connecticut Avenue, N.W. Washington, D.C. 20006 MARCH 14, 1997 -------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d- 1(b)(3) or (4), check the following box [ ]. Check the following box if a fee is being paid with the statement [ ]. (A fee is not required only if the reporting person: (1) has a previous statement on file reporting beneficial ownership of more than five percent of the class of securities described in Item 1; and (2) has filed no amendment subsequent thereto reporting beneficial ownership of five percent or less of such class.) (See Rule 13d-7.) Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. Page 1 of 4 Pages 2 CUSIP No. 503 459 109 - --------------------- - ------------------------------------------------------------------ (1) Name of Reporting Person S.S. or I.R.S. Identification No. of Above Person BB Biotech AG Biotech Target, S.A. - ------------------------------------------------------------------ (2) Check the Appropriate Box if a Member (a) [ ] of a Group (See Instructions) (b) [X] - ------------------------------------------------------------------ (3) SEC Use Only - ------------------------------------------------------------------ (4) Source of Funds (See Instructions) WC - ------------------------------------------------------------------ (5) Check Box if Disclosure of Legal Proceedings [ ] is Required Pursuant to Item 2(d) or 2(e) - ------------------------------------------------------------------ (6) Citizenship or Place of Organization BB Biotech AG -- Switzerland Biotech Target, S.A. -- Panama - ------------------------------------------------------------------ Number of Shares (7) Sole Voting Power Beneficially Owned 0 by BB Biotech AG by Each Reporting --------------------------------- Person With (8) Shared Voting Power 3,071,000 --------------------------------- (9) Sole Dispositive Power 0 by BB Biotech AG --------------------------------- (10) Shared Dispositive Power 3,071,000 --------------------------------- - ------------------------------------------------------------------ (11) Aggregate Amount Beneficially Owned by Each Reporting Person 3,071,000 shares (See Item 5) - ------------------------------------------------------------------ (12) Check Box if the Aggregate Amount in Row (11) [ ] Excludes Certain Shares (See Instructions) - ------------------------------------------------------------------ (13) Percent of Class Represented by Amount in Row (11) 17.7% - ------------------------------------------------------------------ (14) Type of Reporting Person (See Instructions) BB Biotech AG -- HC, CO Biotech Target, S.A. -- CO - ------------------------------------------------------------------ Page 2 of 4 Pages 3 BB Biotech AG ("BB Biotech"), a Swiss corporation, and Biotech Target, S.A., a Panamanian corporation ("Biotech Target") hereby amend their Schedule 13D as originally filed on October 26, 1995. ITEM 5. INTEREST IN SECURITIES OF THE ISSUER. Item 5(a), (b) and (c) of the Schedule 13D are amended to read as follows: (a) BB Biotech may be deemed to be the indirect beneficial owner of the 3,071,000 shares of La Jolla Common Stock held directly by Biotech Target as of July 21, 1997, which represents approximately 17.7% of the outstanding shares of La Jolla Common Stock. No shares of La Jolla Common Stock are directly owned by BB Biotech. To the best knowledge of BB Biotech and Biotech Target, no director or executive officer of BB Biotech or Biotech Target owns any shares of La Jolla Common Stock. (b) The number of shares of La Jolla Common Stock to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or direct the disposition, is set forth in the cover pages hereof and such information is incorporated herein by reference. BB Biotech, through its ownership of Biotech Target, may be deemed to beneficially own the shares of La Jolla Common Stock within the meaning of Regulation 13D under the Exchange Act, and may be deemed to share with Biotech Target the power to vote, or direct the vote of, and the power to dispose of or direct the disposition of, the aggregate 3,071,000 shares of La Jolla Common Stock held by Biotech Target. BB Biotech hereby expressly declares that the filing of this statement shall not be construed as an admission that it is, for purposes of Section 13(d) of the Exchange Act, the beneficial owner of the shares of La Jolla Common Stock held by Biotech Target. (c) A summary of transactions in shares of La Jolla Common Stock effected by Biotech Target during the sixty days prior to the date of the event requiring the filing of this report, and all subsequent transactions therein through and including July 21, 1997, is attached hereto as Exhibit A and such information is incorporated herein by reference. Page 3 of 4 Pages 4 SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. BB BIOTECH AG Date: July 21, 1997 By:/s/ Hans-Joerg Graf* -------------------- Name: Hans-Joerg Graf Date: July 21, 1997 By:/s/ Dr. Victor Bischoff* ------------------------ Name: Dr. Victor Bischoff BIOTECH TARGET, S.A. Date: July 21, 1997 By:/s/ Dr. Andreas Bremer ---------------------- Name: Dr. Andreas Bremer Date: July 21, 1997 By:/s/ Dr. Anders Hove ------------------- Name: Dr. Anders Hove - ------------- * See power of attorney, attached as an exhibit 99.E to the Schedule 13D relating to Biogen, Inc. filed with the Securities and Exchange Commission on June 2, 1994, which exhibit is incorporated by reference herein. Page 4 of 4 Pages 5 Exhibit A Exhibit A is hereby amended to add the following summary of transactions in La Jolla Common Stock effected by Biotech Target during the sixty days prior to the date of the event requiring the filing of this report, and all subsequent transactions therein through and including July 21, 1997.
- ----------------------------------------------------------------------------------------------------------------------------- DATE TYPE OF TRANSACTION AND PURCHASE PRICE BENEFICIALLY OWNED PERCENT OF OUTSTANDING NUMBER OF SHARES OF SHARES PER SHARE SHARES OWNED - ----------------------------------------------------------------------------------------------------------------------------- 3/14/97 Purchase of 315,000 shares 4.93 2,615,000 15.13 - ----------------------------------------------------------------------------------------------------------------------------- 3/21/97 Purchase of 100,000 shares 5.00 2,715,000 15.7 - ----------------------------------------------------------------------------------------------------------------------------- 3/25/97 Purchase of 75,000 shares 5.00 2,790,000 16.1 - ----------------------------------------------------------------------------------------------------------------------------- 3/25/97 Purchase of 50,000 shares 4.88 2,840,000 16.4 - ----------------------------------------------------------------------------------------------------------------------------- 3/26/97 Purchase of 91,000 shares 5.00 2,931,000 16.9 - ----------------------------------------------------------------------------------------------------------------------------- 3/31/97 Purchase of 20,000 shares 4.97 2,951,000 17.0 - ----------------------------------------------------------------------------------------------------------------------------- 4/1/97 Purchase of 10,000 shares 5.03 2,961,000 17.1 - ----------------------------------------------------------------------------------------------------------------------------- 4/2/97 Purchase of 20,000 shares 5.03 2,981,000 17.2 - ----------------------------------------------------------------------------------------------------------------------------- 4/4/97 Purchase of 10,000 shares 5.03 2,991,000 17.3 - ----------------------------------------------------------------------------------------------------------------------------- 4/7/97 Purchase of 80,000 shares 5.09 3,071,000 17.7 - -----------------------------------------------------------------------------------------------------------------------------
-----END PRIVACY-ENHANCED MESSAGE-----